Combined therapy with ipratropium and theophylline in asthma.
Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg) were administered to 24 asthmatics in a randomized double-blind placebo controlled trial. The combination of these agents produced additive bronchodilation for up to two hours, with a 23 percent maximal increase in FEV1. This regimen promises to be safe, effective therapy for patients with asthma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D008875:Middle Aged; D013806:Theophylline / Q000627:therapeutic use*
D001286:Atropine Derivatives; D001993:Bronchodilator Agents; D013806:Theophylline; D009241:Ipratropium